Springworks Therapeutics ( (SWTX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
SpringWorks Therapeutics’ stock has recently gained considerable attention, likely sparked by takeover rumors reported on Ben Harrington’s Betaville blog. This buzz comes as Guggenheim adjusted its price target for the company from $80 to $78, citing revised expectations for its Ogsiveo therapy, particularly regarding ovarian granulosa cell tumors and EU sales projections for 2025. Despite the slight reduction in the price target, Guggenheim still holds a Buy rating, showcasing confidence in SpringWorks’ future prospects.
More about Springworks Therapeutics
YTD Price Performance: 12.22%
Average Trading Volume: 1,168,466
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.01B
For further insights into SWTX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.